Tvardi Therapeutics Inc
↗Sugar Land/Houston, Texas, USA
Tvardi Therapeutics is a clinical-stage, biopharmaceutical company founded in 2017 and based in Houston/Sugar Land, Texas, focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet medical need. The company went public in April 2025 through a merger with Cara Therapeutics and now trades on the NASDAQ under the ticker symbol 'TVRD'. The company is led by experienced entrepreneurs, innovative scientists, and dedicated physicians from MD Anderson Cancer Center, and was recognized by Fierce Biotech as one of 2021's Fierce 15 most promising biotechnology companies. Following the Cara merger, Tvardi retains a lean operational focus with research and development anchored in Houston while managing two critical Phase 2 clinical programs: TTI-101 for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Not disclosed (pre-revenue clinical stage)
Founded:2017
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO/Public
Total Raised:$102M+
Investors:Slate Path Capital, Palkon Capital, ArrowMark Partners, 683 Capital, Sporos Bioventures, Institutional syndicate ($28M private placement April 2025)
STOCK
Exchange:NASDAQ
Ticker:TVRD
Market Cap:$35.18M
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule, Oral inhibitor
Active Trials:2
Trial Phases:Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:MD Anderson Cancer Center (scientific collaboration, founder relationships), NIH/National Cancer Institute (grant funding for TTI-101 development), V Foundation (grant funding), Cancer Prevention and Research Institute of Texas (CPRIT - grant funding), Clinical trial collaborations with major oncology centers
COMPETITION
Position:Emerging
Competitors:Roche/Hoffmann-La Roche (Esbriet/pirfenidone for IPF), Boehringer Ingelheim (Ofev/nintedanib for IPF), Pliant Therapeutics (fibrosis programs), Vicore (pulmonary fibrosis), Gilead Sciences, Blueprint Medicines, Incyte (oncology/HCC), Regeneron (immunotherapy) +2 more
LEADERSHIP
Key Executives:
Imran Alibhai, Ph.D. - Chief Executive Officer
Jeno Gyuris, Ph.D. - Chief Scientific Officer & Chair of Scientific Advisory Board
David Tweardy, M.D. - Co-Founder & Chief Medical Officer
Kari Anne Rowland, M.S. - Vice President of Operations
Joseph Chen, Ph.D. - Vice President of CMC (Chemistry, Manufacturing, Control)
John Kauh, M.D. - Chief Medical Officer/VP Clinical Development
Scientific Founders:David Tweardy, M.D., Ronald A. DePinho, M.D.
Board Members:Ronald A. DePinho, M.D. (Co-Founder, Director), Imran Alibhai, Ph.D. (CEO), Sujal Shah, Michael Wyzga, Cynthia Smith, Dr. Susan Shiff
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Tvardi Therapeutics Inc. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.